By: S. Anand
Professor, Department of Computer Science and Engineering, Infant Jesus College of Engineering, Vallanadu, Tamil Nadu, India
Fibrodysplasia ossificans progressiva (FOP) is an exceptionally rare and debilitating genetic disorder marked by the gradual transformation of soft tissues into bone, severely impairing movement and reducing lifespan. This review delves into the potential of cutting-edge nanotherapy and advanced biosensing technologies as novel strategies for both preventing and treating FOP. Nanotechnology could help make targeted drug delivery systems and real-time monitoring tools that can precisely target the mutant ACVR1 gene, which is at the heart of FOP pathology, and fix the broken bone morphogenetic protein (BMP) signaling pathways that cause the disease. Targeted nanotherapy involves engineering nanoparticles to deliver drugs directly to the mutated gene and modulate the signaling pathways that contribute to aberrant bone formation. By focusing on the specific genetic and molecular mechanisms underlying FOP, this approach aims to mitigate the progression of the disorder and enhance patient outcomes. Concurrently, advanced biosensing technologies offer the capability to monitor the disease in real time, providing critical insights into the efficacy of treatments and the status of disease progression. This review encompasses a thorough examination of the current landscape of FOP research, elucidates the fundamental principles of targeted nanotherapy and biosensing, and explores their potential applications in managing FOP. We discuss relevant case studies, experimental results, and emerging trends in these fields, underscoring both the challenges and opportunities in combating this challenging condition. By integrating these innovative technologies, there is renewed hope for improving the quality of life for individuals with FOP and furthering our comprehension of this complex genetic disorder.
Keywords: Fibrodysplasia ossificans progressiva (FOP), targeted nanotherapy, advanced biosensing, ACVR1 gene, bone morphogenetic protein (BMP) signaling, nanotechnology, drug delivery, real-time monitoring, genetic disorders, personalized medicine
Citation:
Refrences:
1. Tie-Lin Y, Shen H, Liu A, Dong SS, Zhang L, Deng FY, Zhao Q, Deng HW. A road map for understanding molecular and genetic determinants of osteoporosis. Nat Rev Endocrinol. 2020;16(2):91–103. doi:10.1038/s41574-019-0282-7.
2. Haupt J, Deichsel A, Stange K, Ast C, Bocciardi R, Ravazzolo R, Rocco MD, Ferrari P, Landi A, Kaplan FS, Shore EM, Reissner C, Seemann P. ACVR1 p. Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p. Q207D variant. Hum Mol Genet. 2014;23(20):5364–5377. doi:10.1093/hmg/ddu255.
3. Tarannum M, Vivero-Escoto JL. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. Adv Drug Deliv Rev. 2022;187:114357. doi:10.1016/j.addr.2022.114357.
4. Galvin P, Thompson D, Ryan KB, McCarthy A, Moore AC, Burke CS, et al. Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications. Cell Mol Life Sci. 2012;69:389–404. doi:10.1007/s00018-011-0856-6.
5. Ganji MR, Thakur MS. Microprocessor based biosensors for determination of toxins and pathogens in restricted areas of human intervention. Proceedings of the International Conference on Artificial Intelligence, IC-AI’04. 2004;1:525–531.
6. Eswaran U et al. Design and analysis of high sensitive microcantilever based biosensor for CA 15–3 biomarker detection. J Appl Sci Comput. 2018:682–698. doi:16.10089.JASC.2018.V5I7.453459.0050021.
7. Galvin P, Thompson D, Ryan KB, McCarthy A, Moore AC, Burke CS, Dyson M, et al. Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications. Cell Mol Life Sci. 2012;69:389–404. doi:10.1007/s00018-011-0856-6.
8. Holzapfel BM, Reichert JC, Schantz JT, Gbureckm U, Rackwitz L, Noth U, et al. How smart do biomaterials need to be? A translational science and clinical point of view. Adv Drug Deliv Rev. 2013;65(4):581–603. doi:10.1016/j.addr.2012.07.009.
9. Ferreira FJM. Laponite-based nanogels for bone tissue regeneration: optimization and efficacy studies [master’s thesis]. Portugal: Universidade da Madeira; 2020. 1–24.
10. Hsiao EC, Rocco MD, Cali A, Zasloff M, Mukaddam MA, Pignolo RJ, et al. Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP). Br J Clin Pharmacol. 2019;85(6):1199–1207. doi:10.1111/bcp.13777.
11. Cappato S, Giacopelli F, Ravazzolo R, Bocciardi Renata. The horizon of a therapy for rare genetic diseases: a “druggable” future for fibrodysplasia ossificans progressiva. Int J Mol Sci. 2018;19(4):989. doi:10.3390/ijms19040989.
12. Eswaran U, Eswaran V, Murali K, Eswaran V. Application of sensors for smart farming. In: Khang A, editor. Agriculture and Aquaculture Applications of Biosensors and Bioelectronics. Hershey (PA): IGI Global; 2024. 18–44. doi:10.4018/979-8-3693-2069-3.ch002.
13. Eswaran U, Eswaran V, Sudharshan VB. Human like biosensor disease simulator, disease analyzer and drug delivery system. Conference on Information and Communication Technologies. Thuckalay, India. 2013, April 11–12. 1033–1038. IEEE. doi:10.1109/CICT.2013.6558250.
